Top Suppliers:I want be here



Related CAS#:

138530-94-6

138530-94-6 structure
138530-94-6 structure
  • Name: Dexlansoprazole
  • Chemical Name: R-(+)-Lansoprazole
  • CAS Number: 138530-94-6
  • Molecular Formula: C16H14F3N3O2S
  • Molecular Weight: 369.362
  • Catalog: API Digestive system medication Acid and gastric mucosal protective drugs
  • Create Date: 2018-08-11 10:47:55
  • Modify Date: 2024-01-02 09:16:11
  • (R)-Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid.Target: Proton PumpLansoprazole sodium is sodium salt form of lansoprazole, lansoprazole, a substituted benzimidizole proton pump inhibitor, on pharmacokinetics and metabolism of theophylline has been studied in healthy adults given oral lansoprazole 30 mg once daily for 11 days. On Days 4 and 11 of 300 mg aminophylline was simultaneously administered orally and blood samples for theophylline analysis were taken over 24 h [1]. Patients in the lansoprazole group were significantly less likely to have a recurrence of ulcer complications than patients in the placebo group (P=0.008). There was no significant difference in mortality between the two groups [2]. lansoprazole (AG-1749) and omeprazole, were found to have significant activities against this organism. The activity of lansoprazole was comparable to that of bismuth citrate, with MICs ranging from 3.13 to 12.5 micrograms/ml, and fourfold more potent than that of omeprazole [3]. 

Name R-(+)-Lansoprazole
Synonyms Dexlansoprazole
1H-Benzimidazole, 2-[(R)-[(1R)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-
(R)-2-(3-N,N-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenoxyisobutyrate
2-[(R)-{[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl}sulfinyl]-1H-benzimidazole
R-(+)-Lansoprazole
(+)-Lansoprazole
Dexilant
FESO
(R)-lansoprazole
Kapidex
R-lansoprazole
Lansoprazole Impurity 14
Description (R)-Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid.Target: Proton PumpLansoprazole sodium is sodium salt form of lansoprazole, lansoprazole, a substituted benzimidizole proton pump inhibitor, on pharmacokinetics and metabolism of theophylline has been studied in healthy adults given oral lansoprazole 30 mg once daily for 11 days. On Days 4 and 11 of 300 mg aminophylline was simultaneously administered orally and blood samples for theophylline analysis were taken over 24 h [1]. Patients in the lansoprazole group were significantly less likely to have a recurrence of ulcer complications than patients in the placebo group (P=0.008). There was no significant difference in mortality between the two groups [2]. lansoprazole (AG-1749) and omeprazole, were found to have significant activities against this organism. The activity of lansoprazole was comparable to that of bismuth citrate, with MICs ranging from 3.13 to 12.5 micrograms/ml, and fourfold more potent than that of omeprazole [3]. 
Related Catalog
References

[1]. Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48(5): p. 391-5.

[2]. Lai, K.C., et al., Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med, 2002. 346(26): p. 2033-8.

[3]. Iwahi, T., et al., Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother, 1991. 35(3): p. 490-6.

Density 1.5±0.1 g/cm3
Boiling Point 555.8±60.0 °C at 760 mmHg
Melting Point 66-68?C
Molecular Formula C16H14F3N3O2S
Molecular Weight 369.362
Flash Point 289.9±32.9 °C
Exact Mass 369.075867
PSA 87.08000
LogP 2.76
Vapour Pressure 0.0±1.5 mmHg at 25°C
Index of Refraction 1.635
Storage condition Refrigerator
Hazard Codes Xi

~%

138530-94-6 structure

138530-94-6

Literature: WO2010/95144 A2, ; Page/Page column 22 ;

~58%

138530-94-6 structure

138530-94-6

Literature: Del Rio; Wang; Achab; Bohe Organic Letters, 2007 , vol. 9, # 12 p. 2265 - 2268

~%

138530-94-6 structure

138530-94-6

Literature: WO2009/87672 A1, ; Page/Page column 6-8 ;

~%

138530-94-6 structure

138530-94-6

Literature: Tetrahedron Asymmetry, , vol. 14, # 4 p. 407 - 410

~%

138530-94-6 structure

138530-94-6

Literature: Tetrahedron Letters, , vol. 52, # 42 p. 5464 - 5466

~%

138530-94-6 structure

138530-94-6

Literature: Chirality, , vol. 22, # 1 p. 35 - 41